Loss of immune tolerance to IL-2 in type 1 diabetes

@inproceedings{Prol2016LossOI,
  title={Loss of immune tolerance to IL-2 in type 1 diabetes},
  author={Louis P{\'e}rol and John M. Lindner and Pamela C Caudana and Nicol{\'a}s Gonzalo Nu{\~n}ez and Audrey Baeyens and A. Della Valle and Christine Sedlik and Delphine Loirat and Olivier Boyer and Alain Cr{\'e}ange and Jos{\'e} Laurent Cohen and Ute Christine Rogner and Jun Yamanouchi and Martine Marchant and Xavier Charles Leber and Meike Scharenberg and M C Gagnerault and Roberto Mallone and Manuela Battaglia and Pere Santamaria and Agnes Hartemann and Elisabetta Traggiai and Eliane Piaggio},
  booktitle={Nature communications},
  year={2016}
}
Type 1 diabetes (T1D) is characterized by a chronic, progressive autoimmune attack against pancreas-specific antigens, effecting the destruction of insulin-producing β-cells. Here we show interleukin-2 (IL-2) is a non-pancreatic autoimmune target in T1D. Anti-IL-2 autoantibodies, as well as T cells specific for a single orthologous epitope of IL-2, are present in the peripheral blood of non-obese diabetic (NOD) mice and patients with T1D. In NOD mice, the generation of anti-IL-2 autoantibodies… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 13 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 44 references

a phase 1/2 randomised, double-blind, placebo-controlled trial

Hartemann, A. et al. Low-dose interleukin 2 in patients with typ diabetes
Lancet Diabetes Endocrinol. 1, 295–305 • 2013

augments Tregs yet transiently impairs beta - cell function

A. Hartemann
2012

Similar Papers

Loading similar papers…